Genome-Wide Studies in Thyroid Neoplasia

Endocrinology and Metabolism Clinics of North America

Volumn 37, Issue 2, 2008, Pages 311-331

  Giordano, Thomas J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MICRORNA; RADIOACTIVE IODINE;

CANCER MORTALITY; CANCER PATIENT; CARCINOGENESIS; CHROMOSOME DISORDER; DIAGNOSTIC ACCURACY; DRUG TARGETING; GENE EXPRESSION; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW; THYROID MEDULLARY CARCINOMA; THYROID TUMOR; TREATMENT RESPONSE; TUMOR CLASSIFICATION;

CARCINOMA; CHROMOSOMES, HUMAN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; GENOMICS; HUMANS; META-ANALYSIS AS TOPIC; MICRORNAS; THYROID NEOPLASMS; THYROID NODULE; TUMOR MARKERS, BIOLOGICAL;

EID: 44049092787     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2007.12.005     Document Type: Review

References (180)

1. Hirokawa M., Carney J.A., Goellner J.R., et al. Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol 26 11 (2002) 1508-1514
2. Franc B., de la Salmoniere P., Lange F., et al. Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol 34 11 (2003) 1092-1100
3. Lloyd R.V., Erickson L.A., Casey M.B., et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28 10 (2004) 1336-1340
4. Sapio M.R., Posca D., Raggioli A., et al. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 66 5 (2007) 678-683
5. Pizzolanti G., Russo L., Richiusa P., et al. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF(V600E) mutation and RET/PTC rearrangement. Thyroid 17 11 (2007) 1109-1115
6. Kumagai A., Namba H., Akanov Z., et al. Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. Endocr J 54 3 (2007) 399-405
7. Trovisco V., Soares P., and Sobrinho-Simoes M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 37 7 (2006) 781-786
8. Sapio M.R., Posca D., Troncone G., et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 154 2 (2006) 341-348
9. Rowe L.R., Bentz B.G., and Bentz J.S. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 3 (2006) 10
10. Jin L., Sebo T.J., Nakamura N., et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 15 3 (2006) 136-143
11. Chung K.W., Yang S.K., Lee G.K., et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 65 5 (2006) 660-666
12. Xing M., Tufano R.P., Tufaro A.P., et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 89 6 (2004) 2867-2872
13. Jonklaas J. Role of radioactive iodine for adjuvant therapy and treatment of metastases. J Natl Compr Canc Netw 5 6 (2007) 631-640
14. Shaha A.R. Advances in the management of thyroid cancer. Int J Surg 3 3 (2005) 213-220
15. Mizukami Y., Michigishi T., Nonomura A., et al. Distant metastases in differentiated thyroid carcinomas: a clinical and pathologic study. Hum Pathol 21 3 (1990) 283-290
16. Mazzaferri E.L. Management of low-risk differentiated thyroid cancer. Endocr Pract 13 5 (2007) 498-512
17. Hamming J.F., Van de Velde C.J., Goslings B.M., et al. Prognosis and morbidity after total thyroidectomy for papillary, follicular and medullary thyroid cancer. Eur J Cancer Clin Oncol 25 9 (1989) 1317-1323
18. DeGroot L.J., Kaplan E.L., Shukla M.S., et al. Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 80 10 (1995) 2946-2953
19. Witt R.L., and McNamara A.M. Prognostic factors in mortality and morbidity in patients with differentiated thyroid cancer. Ear Nose Throat J 81 12 (2002) 856-863
20. Kingma G., van den Bergen H.A., and de Vries J.E. Prognostic scoring systems in differentiated thyroid carcinoma: which is the best?. Neth J Surg 43 3 (1991) 63-66
21. Sawka A.M., Thephamongkhol K., Brouwers M., et al. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89 8 (2004) 3668-3676
22. Weber F., and Eng C. Gene-expression profiling in differentiated thyroid cancer-a viable strategy for the practice of genomic medicine?. Future Oncol 1 4 (2005) 497-510
23. Mitsiades C.S., Negri J., McMullan C., et al. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol Cancer Ther 6 3 (2007) 1070-1078
24. Salvatore G., De Falco V., Salerno P., et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12 5 (2006) 1623-1629
25. Kim D.W., Jo Y.S., Jung H.S., et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91 10 (2006) 4070-4076
26. Lanzi C., Cassinelli G., Cuccuru G., et al. RET/PTC oncoproteins: molecular targets of new drugs. Tumori 89 5 (2003) 520-522
27. Brentani R.R., Carraro D.M., Verjovski-Almeida S., et al. Gene expression arrays in cancer research: methods and applications. Crit Rev Oncol Hematol 54 2 (2005) 95-105
28. Carter N.P. Methods and strategies for analyzing copy number variation using DNA microarrays. Nat Genet 39 7 Suppl (2007) S16-S21
29. Draghici S., Khatri P., Eklund A.C., et al. Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 22 2 (2006) 101-109
30. Hoheisel J.D. Microarray technology: beyond transcript profiling and genotype analysis. Nat Rev Genet 7 3 (2006) 200-210
31. Lee N.H., and Saeed A.I. Microarrays: an overview. Methods Mol Biol 353 (2007) 265-300
32. Mandruzzato S. Technological platforms for microarray gene expression profiling. Adv Exp Med Biol 593 (2007) 12-18
33. Mockler T.C., Chan S., Sundaresan A., et al. Applications of DNA tiling arrays for whole-genome analysis. Genomics 85 1 (2005) 1-15
34. Petersen D.W., and Kawasaki E.S. Manufacturing of microarrays. Adv Exp Med Biol 593 (2007) 1-11
35. Stoughton R.B. Applications of DNA microarrays in biology. Annu Rev Biochem 74 (2005) 53-82
36. Pollack J.R. A perspective on DNA microarrays in pathology research and practice. Am J Pathol 171 2 (2007) 375-385
37. Venter J.C., Adams M.D., Myers E.W., et al. The sequence of the human genome. Science 291 5507 (2001) 1304-1351
38. Lander E.S., Linton L.M., Birren B., et al. Initial sequencing and analysis of the human genome. Nature 409 6822 (2001) 860-921
39. Schena M., Shalon D., Davis R.W., et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 5235 (1995) 467-470
40. Hanauer D.A., Rhodes D.R., Sinha-Kumar C., et al. Bioinformatics approaches in the study of cancer. Curr Mol Med 7 1 (2007) 133-141
41. Hanai T., Hamada H., and Okamoto M. Application of bioinformatics for DNA microarray data to bioscience, bioengineering and medical fields. J Biosci Bioeng 101 5 (2006) 377-384
42. Szallasi Z. Bioinformatics. Gene expression patterns and cancer. Nat Biotechnol 16 13 (1998) 1292-1293
43. Coleman W.B. Cancer bioinformatics: addressing the challenges of integrated postgenomic cancer research. Cancer Invest 22 1 (2004) 161-163
44. Roberts M.L., and Kottaridis S.D. Interpreting microarray data: towards the complete bioinformatics toolkit for cancer. Cancer Genomics Proteomics 4 4 (2007) 301-308
45. Clark A.G., Eisen M.B., Smith D.R., et al. Evolution of genes and genomes on the Drosophila phylogeny. Nature 450 7167 (2007) 203-218
46. Stark A., Lin M.F., Kheradpour P., et al. Discovery of functional elements in 12 Drosophila genomes using evolutionary signatures. Nature 450 7167 (2007) 219-232
47. Hutchison III C.A. DNA sequencing: bench to bedside and beyond. Nucleic Acids Res 35 18 (2007) 6227-6237
48. Wolinsky H. The thousand-dollar genome. Genetic brinkmanship or personalized medicine?. EMBO Rep 8 10 (2007) 900-903
49. Huang Y., Prasad M., Lemon W.J., et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 98 26 (2001) 15044-15049
50. Giordano T.J., Kuick R., Thomas D.G., et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24 44 (2005) 6646-6656
51. Ciampi R., Giordano T.J., Wikenheiser-Brokamp K., et al. HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocr Relat Cancer 14 2 (2007) 445-452
52. Giordano T.J., Au A.Y., Kuick R., et al. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res 12 7 Pt 1 (2006) 1983-1993
53. Lacroix L., Lazar V., Michiels S., et al. Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol 167 1 (2005) 223-231
54. Lui W.O., Foukakis T., Liden J., et al. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR(gamma) fusion oncogene. Oncogene 24 8 (2005) 1467-1476
55. Kroll T.G., Sarraf P., Pecciarini L., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. [corrected]. Science 289 5483 (2000) 1357-1360
56. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 5748 (2005) 644-648
57. Reddi H.V., McIver B., Grebe S.K., et al. The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis. Endocrinology 148 3 (2007) 932-935
58. Espadinha C., Cavaco B.M., and Leite V. PAX8PPARgamma stimulates cell viability and modulates expression of thyroid-specific genes in a human thyroid cell line. Thyroid 17 6 (2007) 497-509
59. Au A.Y., McBride C., Wilhelm Jr. K.G., et al. PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth. Endocrinology 147 1 (2006) 367-376
60. van Staveren W.C., Solis D.W., Delys L., et al. Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. Proc Natl Acad Sci U S A 103 2 (2006) 413-418
61. Vasko V., Espinosa A.V., Scouten W., et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A 104 8 (2007) 2803-2808
62. Thiery J.P., and Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7 2 (2006) 131-142
63. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2 6 (2002) 442-454
64. Thiery J.P., and Chopin D. Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev 18 1 (1999) 31-42
65. Kokkinos M.I., Wafai R., Wong M.K., et al. Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs 185 1-3 (2007) 191-203
66. Makarewicz C.R. Radiation and thyroid cancer. JAMA 251 10 (1984) 1280
67. Dolphin G.W. Radiation exposure and thyroid cancer. Br J Radiol 45 538 (1972) 795
68. Roudebush C.P., and Asteris G.T. Radiation-associated thyroid cancer. J Indiana State Med Assoc 71 8 (1978) 780-782
69. Roudebush C.P., Asteris G.T., and DeGroot L.J. Natural history of radiation-associated thyroid cancer. Arch Intern Med 138 11 (1978) 1631-1634
70. Sonenberg M., and Leeper R.B. Radiation-induced cancer of the thyroid. Clin Bull 8 1 (1978) 29-33
71. Curtin C.T., McHeffy B., and Kolarsick A.J. Thyroid and breast cancer following childhood radiation. Cancer 40 6 (1977) 2911-2913
72. Williamson M.E. Thyroid cancer following exposure to ionizing radiation. J Am Osteopath Assoc 76 11 (1977) 98-101
73. Greenspan F.S. Radiation exposure and thyroid cancer. JAMA 237 19 (1977) 2089-2091
74. DeGroot L.J. Radiation and thyroid cancer. Proc Inst Med Chic 31 4 (1976) 95-96
75. Asteris G.T., and DeGroot L.J. Thyroid cancer: relationship to radiation exposure and to pregnancy. J Reprod Med 17 4 (1976) 209-216
76. Debra Jr. D.W. Radiation and thyroid cancer. New concerns. J Med Assoc Ga 64 10 (1975) 395-396
77. Dolphin G.W. Thyroid cancer: radiation carcinogenesis. Recent Results Cancer Res 73 (1980) 23-30
78. Duffy Jr. B.J. Can radiation cause thyroid cancer. J Clin Endocrinol Metab 17 11 (1957) 1383-1388
79. Ivanov V.K., Gorski A.I., Tsyb A.F., et al. Radiation-epidemiological studies of thyroid cancer incidence among children and adolescents in the Bryansk oblast of Russia after the Chernobyl accident (1991-2001 follow-up period). Radiat Environ Biophys 45 1 (2006) 9-16
80. Kopecky K.J., Stepanenko V., Rivkind N., et al. Childhood thyroid cancer, radiation dose from Chernobyl, and dose uncertainties in Bryansk Oblast, Russia: a population-based case-control study. Radiat Res 166 2 (2006) 367-374
81. Minenko V.F., Ulanovsky A.V., Drozdovitch V.V., et al. Individual thyroid dose estimates for a case-control study of Chernobyl-related thyroid cancer among children of Belarus-part II. Contributions from long-lived radionuclides and external radiation. Health Phys 90 4 (2006) 312-327
82. Nikiforov Y.E. Radiation-induced thyroid cancer: what we have learned from Chernobyl. Endocr Pathol 17 4 (2006) 307-317
83. Detours V., Delys L., Libert F., et al. Genome-wide gene expression profiling suggests distinct radiation susceptibilities in sporadic and post-Chernobyl papillary thyroid cancers. Br J Cancer 97 6 (2007) 818-825
84. Detours V., Wattel S., Venet D., et al. Absence of a specific radiation signature in post-Chernobyl thyroid cancers. Br J Cancer 92 8 (2005) 1545-1552
85. Aldred M.A., Huang Y., Liyanarachchi S., et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22 17 (2004) 3531-3539
86. Barden C.B., Shister K.W., Zhu B., et al. Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 9 5 (2003) 1792-1800
87. Eszlinger M., Wiench M., Jarzab B., et al. Meta- and reanalysis of gene expression profiles of hot and cold thyroid nodules and papillary thyroid carcinoma for gene groups. J Clin Endocrinol Metab 91 5 (2006) 1934-1942
88. Finley D.J., Zhu B., Barden C.B., et al. Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 240 3 (2004) 425-436 [discussion: 436-7]
89. Fontaine J.F., Mirebeau-Prunier D., Franc B., et al. Microarray analysis refines classification of non-medullary thyroid tumours of uncertain malignancy. Oncogene (2007) [epub ahead of print]
90. Fujarewicz K., Jarzab M., Eszlinger M., et al. A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr Relat Cancer 14 3 (2007) 809-826
91. Griffith O.L., Melck A., Jones S.J., et al. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 24 31 (2006) 5043-5051
92. Jarzab B., Wiench M., Fujarewicz K., et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 65 4 (2005) 1587-1597
93. Lubitz C.C., Gallagher L.A., Finley D.J., et al. Molecular analysis of minimally invasive follicular carcinomas by gene profiling. Surgery 138 6 (2005) 1042-1048 [discussion: 1048-49]
94. Lubitz C.C., Ugras S.K., Kazam J.J., et al. Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J Mol Diagn 8 4 (2006) 490-498 [quiz: 528]
95. Mazzanti C., Zeiger M.A., Costouros N.G., et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 64 8 (2004) 2898-2903
96. Weber F., Shen L., Aldred M.A., et al. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab 90 5 (2005) 2512-2521
97. Yano Y., Uematsu N., Yashiro T., et al. Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res 10 6 (2004) 2035-2043
98. Yukinawa N., Oba S., Kato K., et al. A multi-class predictor based on a probabilistic model: application to gene expression profiling-based diagnosis of thyroid tumors. BMC Genomics 7 (2006) 190
99. Lubitz C.C., and Fahey III T.J. Gene expression profiling of thyroid tumors-clinical applicability. Nat Clin Pract Endocrinol Metab 2 9 (2006) 472-473
100. Simon R., Radmacher M.D., Dobbin K., et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95 1 (2003) 14-18
101. Belacel N., Wang Q., and Cuperlovic-Culf M. Clustering methods for microarray gene expression data. OMICS 10 4 (2006) 507-531
102. Breitling R. Biological microarray interpretation: the rules of engagement. Biochim Biophys Acta 1759 7 (2006) 319-327
103. Dupuy A., and Simon R.M. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99 2 (2007) 147-157
104. Ness S.A. Basic microarray analysis: strategies for successful experiments. Methods Mol Biol 316 (2006) 13-33
105. Weeraratna A.T., and Taub D.D. Microarray data analysis: an overview of design, methodology, and analysis. Methods Mol Biol 377 (2007) 1-16
106. Williams E.D. Guest editorial: two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol 8 3 (2000) 181-183
107. Wreesmann V.B., Sieczka E.M., Socci N.D., et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64 11 (2004) 3780-3789
108. Zou M., Famulski K.S., Parhar R.S., et al. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab 89 12 (2004) 6146-6154
109. Zou M., Al-Baradie R.S., Al-Hindi H., et al. S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. Br J Cancer 93 11 (2005) 1277-1284
110. Siraj A.K., Bavi P., Abubaker J., et al. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J Pathol 213 2 (2007) 190-199
111. Christensen J.G., Burrows J., and Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225 1 (2005) 1-26
112. Egger G., Liang G., Aparicio A., et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429 6990 (2004) 457-463
113. Rosai J. Why microscopy will remain a cornerstone of surgical pathology. Lab Invest 87 5 (2007) 403-408
114. Giordano T.J. Molecular profiling and personalized predictive pathology: challenge to the academic surgical pathology community. Am J Surg Pathol 30 3 (2006) 402-404
115. Miska E.A. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 15 5 (2005) 563-568
116. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 435 7043 (2005) 834-838
117. Yanaihara N., Caplen N., Bowman E., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9 3 (2006) 189-198
118. Blower P.E., Verducci J.S., Lin S., et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 6 5 (2007) 1483-1491
119. Lui W.O., Pourmand N., Patterson B.K., et al. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 67 13 (2007) 6031-6043
120. Zanette D.L., Rivadavia F., Molfetta G.A., et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res 40 11 (2007) 1435-1440
121. Zhang B., Pan X., Cobb G.P., et al. microRNAs as oncogenes and tumor suppressors. Dev Biol 302 1 (2007) 1-12
122. Visone R., Pallante P., Vecchione A., et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26 54 (2007) 7590-7595
123. Weber F., Teresi R.E., Broelsch C.E., et al. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 91 9 (2006) 3584-3591
124. Pallante P., Visone R., Ferracin M., et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 13 2 (2006) 497-508
125. He H., Jazdzewski K., Li W., et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 102 52 (2005) 19075-19080
126. Kondo T., Ezzat S., and Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6 4 (2006) 292-306
127. Weir B.A., Woo M.S., Getz G., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450 7171 (2007) 893-898
128. Chen X., Knauf J.A., Gonsky R., et al. From amplification to gene in thyroid cancer: a high-resolution mapped bacterial-artificial-chromosome resource for cancer chromosome aberrations guides gene discovery after comparative genome hybridization. Am J Hum Genet 63 2 (1998) 625-637
129. Hemmer S., Wasenius V.M., Knuutila S., et al. Comparison of benign and malignant follicular thyroid tumours by comparative genomic hybridization. Br J Cancer 78 8 (1998) 1012-1017
130. Frisk T., Kytola S., Wallin G., et al. Low frequency of numerical chromosomal aberrations in follicular thyroid tumors detected by comparative genomic hybridization. Genes Chromosomes Cancer 25 4 (1999) 349-353
131. Hemmer S., Wasenius V.M., Knuutila S., et al. DNA copy number changes in thyroid carcinoma. Am J Pathol 154 5 (1999) 1539-1547
132. Komoike Y., Tamaki Y., Sakita I., et al. Comparative genomic hybridization defines frequent loss on 16p in human anaplastic thyroid carcinoma. Int J Oncol 14 6 (1999) 1157-1162
133. Tallini G., Hsueh A., Liu S., et al. Frequent chromosomal DNA unbalance in thyroid oncocytic (Hurthle cell) neoplasms detected by comparative genomic hybridization. Lab Invest 79 5 (1999) 547-555
134. Singh B., Lim D., Cigudosa J.C., et al. Screening for genetic aberrations in papillary thyroid cancer by using comparative genomic hybridization. Surgery 128 6 (2000) 888-893 [discussion: 893-4]
135. Wilkens L., Benten D., Tchinda J., et al. Aberrations of chromosomes 5 and 8 as recurrent cytogenetic events in anaplastic carcinoma of the thyroid as detected by fluorescence in situ hybridisation and comparative genomic hybridisation. Virchows Arch 436 4 (2000) 312-318
136. Kjellman P., Lagercrantz S., Hoog A., et al. Gain of 1q and loss of 9q21.3-q32 are associated with a less favorable prognosis in papillary thyroid carcinoma. Genes Chromosomes Cancer 32 1 (2001) 43-49
137. Bauer A.J., Cavalli L.R., Rone J.D., et al. Evaluation of adult papillary thyroid carcinomas by comparative genomic hybridization and microsatellite instability analysis. Cancer Genet Cytogenet 135 2 (2002) 182-186
138. Corso C., Ulucan H., Parry E.M., et al. Comparative analysis of two thyroid tumor cell lines by fluorescence in situ hybridization and comparative genomic hybridization. Cancer Genet Cytogenet 137 2 (2002) 108-118
139. Wreesmann V.B., Ghossein R.A., Patel S.G., et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol 161 5 (2002) 1549-1556
140. Brunaud L., Zarnegar R., Wada N., et al. Chromosomal aberrations by comparative genomic hybridization in thyroid tumors in patients with familial nonmedullary thyroid cancer. Thyroid 13 7 (2003) 621-629
141. Dettori T., Frau D.V., Lai M.L., et al. Aneuploidy in oncocytic lesions of the thyroid gland: diffuse accumulation of mitochondria within the cell is associated with trisomy 7 and progressive numerical chromosomal alterations. Genes Chromosomes Cancer 38 1 (2003) 22-31
142. Miura D., Wada N., Chin K., et al. Anaplastic thyroid cancer: cytogenetic patterns by comparative genomic hybridization. Thyroid 13 3 (2003) 283-290
143. Roque L., Rodrigues R., Pinto A., et al. Chromosome imbalances in thyroid follicular neoplasms: a comparison between follicular adenomas and carcinomas. Genes Chromosomes Cancer 36 3 (2003) 292-302
144. Richter H., Braselmann H., Hieber L., et al. Chromosomal imbalances in post-Chernobyl thyroid tumors. Thyroid 14 12 (2004) 1061-1064
145. Rodrigues R.F., Roque L., Rosa-Santos J., et al. Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. Br J Cancer 90 2 (2004) 492-496
146. Wreesmann V.B., Ghossein R.A., Hezel M., et al. Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity. Genes Chromosomes Cancer 40 4 (2004) 355-364
147. Castro P., Eknaes M., Teixeira M.R., et al. Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. J Pathol 206 3 (2005) 305-311
148. Foukakis T., Thoppe S.R., Lagercrantz S., et al. Molecular cytogenetic characterization of primary cultures and established cell lines from non-medullary thyroid tumors. Int J Oncol 26 1 (2005) 141-149
149. Finn S., Smyth P., O'Regan E., et al. Low-level genomic instability is a feature of papillary thyroid carcinoma: an array comparative genomic hybridization study of laser capture microdissected papillary thyroid carcinoma tumors and clonal cell lines. Arch Pathol Lab Med 131 1 (2007) 65-73
150. Lee J.J., Foukakis T., Hashemi J., et al. Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models. Thyroid 17 4 (2007) 289-301
151. Rodrigues R., Roque L., Espadinha C., et al. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas. Oncol Rep 18 4 (2007) 917-926
152. Stoler D.L., Nowak N.J., Matsui S., et al. Comparative genomic instabilities of thyroid and colon cancers. Arch Otolaryngol Head Neck Surg 133 5 (2007) 457-463
153. Kallioniemi A., Kallioniemi O.P., Sudar D., et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258 5083 (1992) 818-821
154. Pinkel D., and Albertson D.G. Array comparative genomic hybridization and its applications in cancer. Nat Genet 37 Suppl (2005) S11-S17
155. Kimmel R.R., Zhao L.P., Nguyen D., et al. Microarray comparative genomic hybridization reveals genome-wide patterns of DNA gains and losses in post-Chernobyl thyroid cancer. Radiat Res 166 3 (2006) 519-531
156. Rosai J. Poorly differentiated thyroid carcinoma: introduction to the issue, its landmarks, and clinical impact. Endocr Pathol 15 4 (2004) 293-296
157. Sakamoto A. Definition of poorly differentiated carcinoma of the thyroid: the Japanese experience. Endocr Pathol 15 4 (2004) 307-311
158. Albores-Saavedra J., and Carrick K. Where to set the threshold between well differentiated and poorly differentiated follicular carcinomas of the thyroid. Endocr Pathol 15 4 (2004) 297-305
159. Nikiforov Y.E. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 15 4 (2004) 319-327
160. Kim J.H., Dhanasekaran S.M., Mehra R., et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 67 17 (2007) 8229-8239
161. Tomlins S.A., Mehra R., Rhodes D.R., et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39 1 (2007) 41-51
162. Varambally S., Yu J., Laxman B., et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8 5 (2005) 393-406
163. Jain S., Watson M.A., DeBenedetti M.K., et al. Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. Cancer Res 64 11 (2004) 3907-3913
164. Nakamichi Y., Shukunami C., Yamada T., et al. Chondromodulin I is a bone remodeling factor. Mol Cell Biol 23 2 (2003) 636-644
165. Marsh D.J., Theodosopoulos G., Martin-Schulte K., et al. Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 88 4 (2003) 1866-1872
166. Ruiz-Llorente S., Montero-Conde C., Milne R.L., et al. Association study of 69 genes in the RET pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma. Cancer Res 67 19 (2007) 9561-9567
167. Denning K.M., Smyth P.C., Cahill S.F., et al. A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples. Mod Pathol 20 10 (2007) 1095-1102
168. Foukakis T., Gusnanto A., Au A.Y., et al. A PCR-based expression signature of malignancy in follicular thyroid tumors. Endocr Relat Cancer 14 2 (2007) 381-391
169. Rosen J., He M., Umbricht C., et al. A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Surgery 138 6 (2005) 1050-1056 [discussion: 1056-7]
170. Lu Y., Lemon W., Liu P.Y., et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 3 12 (2006) 2229-2243
171. Furlow B. Gene-expression profiles predict secondary leukaemia risk. Lancet Oncol 7 4 (2006) 287
172. Desmedt C., Piette F., Loi S., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13 11 (2007) 3207-3214
173. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 9460 (2005) 671-679
174. Spentzos D., Levine D.A., Ramoni M.F., et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22 23 (2004) 4700-4710
175. Parissenti A.M., Hembruff S.L., Villeneuve D.J., et al. Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells. Anticancer Drugs 18 5 (2007) 499-523
176. Kim I.J., Lim S.B., Kang H.C., et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 50 9 (2007) 1342-1353
177. Jensen E.H., McLoughlin J.M., and Yeatman T.J. Microarrays in gastrointestinal cancer: is personalized prediction of response to chemotherapy at hand?. Curr Opin Oncol 18 4 (2006) 374-380
178. Takata R., Katagiri T., Kanehira M., et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11 7 (2005) 2625-2636
179. Selvanayagam Z.E., Cheung T.H., Wei N., et al. Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet 154 1 (2004) 63-66
180. Mariadason J.M., Arango D., Shi Q., et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 63 24 (2003) 8791-8812